Amdocs Limited DOX
62.43 USD -1.11 (-1.75%)
At closeNov 3, 2026, 4:00 PM EST
62.43 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
61.67 Day range 62.95
49.74 52-week range 85.63
- YTD
- -22.46%
- 1 year
- -25.79%
Analyst view
Price target (mean) 79.25 +26.9% upside
Now 62.43
- Target (low)
- 63.00
- Target (mean)
- 79.25
- Target (high)
- 105.00
Ratings (0m) 6 3 buy · 3 hold · 0 sell
- Strong buy0
- Buy3
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 1.98 | 1.96 – 2.01 | 1.83 | +8.1% | 1.19B | +3.9% | 5 |
| Next quarter | 1.93 | 1.91 – 1.96 | 1.81 | +6.8% | 1.20B | +3.8% | 4 |
| Current year | 7.42 | 7.40 – 7.45 | 6.99 | +6.2% | 4.70B | +3.7% | 6 |
| Next year | 8.03 | 7.83 – 8.29 | 7.42 | +8.2% | 4.85B | +3.2% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 29, 2026 | Keybanc | Initiated | — | Sector Weight |
| May 14, 2026 | Stifel | Maintained | Buy | Buy |
| Feb 5, 2026 | Barclays | Maintained | Overweight | Overweight |
| Feb 4, 2026 | Stifel | Maintained | Buy | Buy |
| Nov 13, 2025 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Nov 12, 2025 | Stifel | Maintained | Buy | Buy |
| Nov 12, 2025 | B of A Securities | Maintained | Buy | Buy |
| Jul 8, 2025 | Wolfe Research | Initiated | — | Outperform |
| Nov 14, 2024 | Barclays | Maintained | Overweight | Overweight |
| Nov 13, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Oct 2, 2024 | Stifel | Initiated | — | Buy |
| May 9, 2024 | Citigroup | Maintained | Buy | Buy |
| May 9, 2024 | Baird | Maintained | Neutral | Neutral |
| Feb 8, 2024 | Barclays | Maintained | Overweight | Overweight |
| Jan 17, 2024 | Citigroup | Maintained | Buy | Buy |
| Dec 1, 2023 | Jefferies | Initiated | — | Buy |
| Aug 3, 2023 | Oppenheimer | Maintained | Outperform | Outperform |
| May 16, 2023 | Barclays | Upgrade | Equal-Weight | Overweight |
| May 11, 2023 | Oppenheimer | Reiterated | Outperform | Outperform |
| Feb 2, 2023 | Baird | Maintained | — | Neutral |
| Feb 1, 2023 | Oppenheimer | Maintained | — | Outperform |
| Nov 9, 2022 | Citigroup | Maintained | — | Buy |
| Aug 4, 2022 | Barclays | Maintained | — | Equal-Weight |
| Aug 4, 2022 | Citigroup | Maintained | — | Buy |
| May 12, 2022 | Citigroup | Maintained | — | Buy |
| Dec 14, 2021 | JP Morgan | Downgrade | Overweight | Neutral |
| Aug 5, 2021 | Oppenheimer | Maintained | — | Outperform |
| Nov 11, 2020 | JP Morgan | Upgrade | Neutral | Overweight |
| May 11, 2020 | Citigroup | Maintained | — | Buy |
| Feb 5, 2020 | Baird | Maintained | — | Neutral |